Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of a 4-week Treatment of 15 and 30 mg b.i.d BIBW2948 BS (Inhalation Powder, Hard Capsule for HandiHaler®) on Epithelial Mucin Stores and the Safety and Efficacy in COPD Patients With Symptoms Associated With Chronic Bronchitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2021
Price :
$35
*
At a glance
- Drugs BIBW 2948 BS (Primary)
- Indications Chronic bronchitis; Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 14 Sep 2009 The primary endpoint, Change in airway eipthelial mucin volume, was not met.
- 14 Sep 2009 Results were presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009).
- 27 Jul 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.